Health, Fitness & Food

Enfimil infant formula, made by Mead Johnson Nutrition Co., sits on display in a supermarket in New York, U.S. Daniel Acker | Bloomberg News | Getty Images Baby formula maker Reckitt Benckiser’s Mead Johnson Nutrition has voluntarily chosen to recall certain batches of baby formula powder due to possible bacterial contamination, according to the U.S.
0 Comments
In this article WBA Follow your favorite stocksCREATE FREE ACCOUNT Walgreens reported fiscal first-quarter adjusted earnings and revenue that topped expectations on Thursday, but cut its quarterly dividend nearly in half.  The retail pharmacy giant slashed its dividend to 25 cents per share from 48 cents per share to “strengthen [its] long-term balance sheet and cash
0 Comments
In this article MRNA Follow your favorite stocksCREATE FREE ACCOUNT Artur Widak | Nurphoto | Getty Images Shares of Moderna jumped more than 15% on Tuesday after Oppenheimer upgraded the stock to “outperform,” saying the Covid vaccine maker could market five products by 2026. The upgrade follows a dismal 2023 for Moderna, whose only commercially
0 Comments
In this article LLY Follow your favorite stocksCREATE FREE ACCOUNT Sopa Images | Lightrocket | Getty Images Eli Lilly is shaking up the pharmaceutical industry with a new website offering telehealth prescriptions and direct home delivery of certain drugs, including its red-hot weight loss treatment Zepbound, to expand patient access.  The company’s direct-to-consumer push announced
0 Comments
In this article MRNA Follow your favorite stocksCREATE FREE ACCOUNT Nikos Pekiaridis | Lightrocket | Getty Images Moderna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab. The revenue from the shots met Moderna’s
0 Comments
People walk past a billboard advertisement for YouTube in Berlin, Germany, on Sept. 27, 2019. Sean Gallup | Getty Images YouTube is taking steps to fight against medical misinformation, especially when it comes to finding immediate tips on how to handle an emergency. The company on Wednesday introduced a feature called First Aid Information Shelves,
0 Comments
We’re making our first Bullpen update of 2024. The Bullpen is a collection of stocks identified by the CNBC Investing Club team as having the potential to join Jim Cramer’s Charitable Trust. We’re highlighting the four most interesting investment opportunities we found out of the handful of company CEOs Jim interviewed at this week’s JPMorgan
0 Comments
In this article NOVO.B-DK LLY Follow your favorite stocksCREATE FREE ACCOUNT George Frey | Reuters Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to
0 Comments
Woman with Signos wearable and app Source: Signos Weight loss has always been big business, but it’s exploded of late due to surging demand for Ozempic, Wegovy and other new diabetes and obesity drugs. In the first half of 2023, sales of Ozempic and Wegovy rose by 58% and 363%, respectively. That’s after quarterly prescriptions
0 Comments
We’re buying 30 shares of Danaher (DHR) at roughly $199 each. Following Tuesday’s trade, Jim Cramer’s Charitable Trust will own 550 shares of DHR, increasing its weighting in the portfolio to 4.08% from 3.87%. Danaher reported a better-than-expected third-quarter Tuesday morning, but the stock is under pressure in early trading due to uncertainty around the
0 Comments
In this article WMT AMZN Follow your favorite stocksCREATE FREE ACCOUNT Photo courtesy of Amazon Amazon is considering an expansion into veterinary telehealth in its latest bid to compete with Walmart, which began offering the service to Walmart+ subscribers earlier this year, people familiar with the matter told CNBC.  The e-commerce giant, which has already
0 Comments
Eisai | via Reuters Eisai on Wednesday said an injectable version of the Alzheimer’s drug Leqembi showed promising initial results in a clinical trial, potentially paving the way for a new and more convenient option for administering the antibody treatment.  However, the injection did not cause lower rates of brain swelling and bleeding, which are
0 Comments
In this article BMY Follow your favorite stocksCREATE FREE ACCOUNT Dado Ruvic | Reuters Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company’s popular blood cancer drug Revlimid plummeted due to generic competition.  Bristol Myers, one of the world’s
0 Comments